357 research outputs found
[Book Review of] \u3cem\u3eLiving with Dying: The Management of Terminal Disease\u3c/em\u3e, by Dame Cicily Saunders and Mary Baines
Get PDF[Book Review of] \u3cem\u3eSuicide and Euthanasia: The Rights of Personhood\u3c/em\u3e, edited by Samuel E. Wallace and Albin Eser
Get PDF[Book Review of] \u3cem\u3ePsychiatric Ethics\u3c/em\u3e, by Brian V. Johnstone, edited by Sidney Bloch and Paul Chodoff
Get PDF
[Book Review of] \u3cem\u3eEthics from a Theocentric Perspective, Vol. 1 Theology and Ethics\u3c/em\u3e, by James M. Gustafson and [Book Review of] Ethics from a Theocentric Perspective, Vol. 2 Ethics and Theology, by James M. Gustafson
Get PDF[Book Review of] \u3cem\u3eHealth/Medicine and the Faith Traditions: An Inquiry into Religion and Medicine\u3c/em\u3e, edited by Martin E. Marty and Kenneth L. Vaux
Get PDF[Book Review of] \u3cem\u3eFrom Chance to Purpose: An Appraisal of External Human Fertilization,\u3c/em\u3e by Clifford Grobstein
Get PDF
EMPHYMAB BIOTECH, MEDICAL THERAPIES FOR EMPHYSEMA
Get PDFposter abstractEmphymab™ Biotech was formed to develop and commercialize medical therapies that address serious lung diseases. The founders are scientists and clinicians at Indiana University School of Medicine. Emphymab’s lead technology is based on a novel monoclonal antibody that inactivates a newly discovered pathway involved in lung diseases and, thereby, halts progressive loss of lung function associated with emphysema. This technology has the potential to address the huge unmet medical need of patients suffering from chronic obstructive pulmonary disease (COPD) with emphysema, which is the 3rd leading cause of death worldwide
- …
